Hemodynamic Monitoring Equally Reduces Heart Failure Hospitalizations in Women and Men in Clinical Practice: CardioMEMS Post-Approval Study

Introduction Sex is often associated with divergent outcomes in cardiovascular disease. Response to pharmacologic and device-based therapy for heart failure (HF) may vary by sex, yet women are often underrepresented in clinical trials. We sought to examine possible sex differences in the response to ambulatory hemodynamic monitoring in clinical practice using the CardioMEMS Post-Approval Study (PAS). Methods The PAS was a prospective, single arm, multi-center, open-label study of 1200 adults (>18 years) with NYHA Class III HF and at least one HF hospitalization (HFH) within 12 months. Changes in PAP over time were stratified by EF ( Results The 452 (38% of total) women enrolled in the PAS were less likely to be white (78% vs. 86%, p Conclusions Women and men enrolled in the PAS had similar reductions from baseline in PAP over 1 year and experienced similar reductions in HFH at one year compared with the year prior. There were no differences in all-cause mortality between women and men when adjusting for baseline covariates. Hemodynamic monitoring provides similar benefit with regard to HF events in both women and men.